10559885

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new

```
                  custom IPC display formats
 NEWS 32  JAN 28  MARPAT searching enhanced
 NEWS 33  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 34  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36  FEB 08  STN Express, Version 8.3, now available
 NEWS 37  FEB 20  PCI now available as a replacement to DPCI


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:44:20 ON 22 FEB 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:44:32 ON 22 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 FEB 2008  HIGHEST RN 1005032-28-9
DICTIONARY FILE UPDATES:  21 FEB 2008  HIGHEST RN 1005032-28-9
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10559885.str





chain nodes :
16 17 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
3-16 5-20 9-17 11-16
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-15 12-13 13-14 14-15
exact/norm bonds :
3-16 5-20 9-17 11-15 11-16 14-15
exact bonds :
5-6 5-10 7-8 8-9 9-10 11-12 12-13 13-14

normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 : 11 :

G1:SO2,S,SO3H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 20:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



G1 SO2,S,SO3H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:44:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6 TO ITERATE

100.0% PROCESSED   6 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 6 TO   266
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:44:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   92 TO ITERATE

100.0% PROCESSED   92 ITERATIONS   0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10559885a.str





chain nodes :
11 12 15 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-11 5-15 9-12 11-16
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
3-11 5-15 9-12 11-16
exact bonds :
5-6 5-10 7-8 8-9 9-10
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 :

G1:SO2,S,SO3H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 15:CLASS 16:Atom

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS

L4 STR



G1 SO2,S,SO3H

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 12:46:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      258 TO ITERATE

100.0% PROCESSED      258 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4197 TO     6123
PROJECTED ANSWERS:               2 TO      124

L5            2 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 12:46:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     5177 TO ITERATE

100.0% PROCESSED     5177 ITERATIONS                             29 ANSWERS
SEARCH TIME: 00.00.01

L6           29 SEA SSS FUL L4

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             357.64     357.85

FILE 'HCAPLUS' ENTERED AT 12:46:57 ON 22 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 22 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 21 Feb 2008 (20080221/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l6
L7          10 L6

=> s l7 and py<=2003
      23977297 PY<=2003
L8           5 L7 AND PY<=2003

=> s l7 and leukotriene
          14866 LEUKOTRIENE
           8234 LEUKOTRIENES
          17143 LEUKOTRIENE
                (LEUKOTRIENE OR LEUKOTRIENES)
L9           0 L7 AND LEUKOTRIENE

=> d l8 ibib abs hitstr tot
```

L8 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:991527 HCAPLUS
DOCUMENT NUMBER: 140:28025
TITLE: Preparation of cyclic nucleotides for modulating the activity of exchange proteins directly activated by cAMP (Epacs)
INVENTOR(S): De Koning, John; Christensen, Anne; Schwede, Frank; Genieser, Hans Gottfried; Doskeland, Stein; Bos, Johannes
PATENT ASSIGNEE(S): Kylix, B. V., Neth.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104250	A1	20031218	WO 2003-EP6120	20030610 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2488611 A1 20031218 CA 2003-2488611 20030610 <--
AU 2003242672 A1 20031222 AU 2003-242672 20030610 <--
EP 1511757 A1 20050309 EP 2003-757062 20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005532360 T 20051027 JP 2004-511318 20030610
US 2006100166 A1 20060511 US 2005-517564 20051215
PRIORITY APPLN. INFO.: EP 2002-77219 A 20020607
WO 2003-EP6120 W 20030610
OTHER SOURCE(S): MARPAT 140:28025
GI



I

AB The present invention relates to novel cyclic nucleotides I and deaza analogs, wherein R1 can be independently H, halogen, azido, alkyl, aryl, amido-alkyl, amido-aryl, OH, O-alkyl, O-aryl, SH, S-alkyl, Saryl, SeH, Se-alkyl, Se-aryl, amino, NH-alkyl, NH-aryl, Nbisalkyl, N-bisaryl, cycloalkylamino; R2 can be independently H, halogen, azido, O-alkyl, Salkyl, Se-alkyl, NH-alkyl, N-bisalkyl, alkyl-carbamoyl, cycloalkylamino, silyl; R3 can be independently H, halogen, OH, azido, amidoalkyl, amido-aryl, O-alkyl, O-aryl, SH, S-alkyl, S-aryl, amino, NH-alkyl, NH-aryl, N-bisalkyl, N-bisaryl, NH-alkylcarbamoyl, cycloalkylamino; and wherein R4 is O(H) or S(H); and R5 is O(H), S(H), amino, H, alkyl, O-alkyl, O-aryl, S-alkyl, S-aryl, NH-alkyl, NH-aryl, N-bisalkyl, N-bisaryl; or R4is O(H), S(H), amino, H, alkyl, O-alkyl, O-aryl, Salkyl, S-aryl, NH-alkyl, NH-aryl, N-bisalkyl, N-bisaryl; and R5 is O(H) or S(H); for modulating the activity of exchange proteins directly activated by cAMP (Epacs). In particular, the present invention relates to cAMP analogs that specifically modulate the activity of Epacs. The invention further relates to pharmaceutical compns. comprising the novel compds., and the use of the compds. in the treatment of humans and/or animals. Cyclic nucleotides were prepared as antitumor, antithrombotic, and antiinflammatory agents, for discriminating between Epac- and PKA-mediated signal transduction pathways, and for R10 the treatment of type-2 diabetes mellitus. Thus, 8-bromo-2'-deoxyadenosine-3',5'-cyclic monophosphate was prepared and tested for modulating the activity of exchange proteins directly activated by cAMP.for modulating the activity of exchange proteins directly activated by cAMP. In summary, these findings suggest

multiple therapeutic applications for cAMP analogs that specifically modulate the activity of Epacs, like 2'-O-Me-cAMP, including treatment of cancer, chronic inflammation, thrombosis, and type-2 diabetes mellitus. In addition, a large number of other new compds. were tested for their effect on Epac and PKA. Since phosphorothioate-modified cyclic nucleotides are known to be considerably protected from hydrolysis by cyclic nucleotide responsive phosphodiesterases (PDE), corresponding analogs were prepared as well, in order to obtain PDE-resistant tools, where necessary, e.g. for long term incubation expts.

IT 634207-77-5P 634208-08-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic nucleotides for modulating activity of exchange proteins directly activated by camp epacs)

RN 634207-77-5 HCAPLUS
CN Adenosine, 2'-O-methyl-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-, cyclic 3',5'-(hydrogen phosphate), monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 634208-08-5 HCAPLUS
CN Adenosine, 2'-O-methyl-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-, cyclic 3',5'-(hydrogen phosphate) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:144986 HCAPLUS
DOCUMENT NUMBER: 136:290922
TITLE: 4-Methyl-7-thioumbelliferyl-β-D-cellobioside: A Fluorescent, Nonhydrolyzable Substrate Analogue for Cellulases
AUTHOR(S): Barr, Brian K.; Holewinski, Ronald J.
CORPORATE SOURCE: Department of Chemistry, Loyola College in Maryland, Baltimore, MD, 21210-2699, USA
SOURCE: Biochemistry (2002), 41(13), 4447-4452
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:290922
AB The kinetics of cellulose binding and hydrolysis by cellulases is not well understood except at steady-state conditions. For use in studies of cellulase pre-steady-state and steady-state kinetics, we have prepared 4-methyl-7-thioumbelliferyl-β-D-cellobioside (MUS-CB), a ground-state nonhydrolyzable analog of the fluorescent cellulase substrate 4-methylumbelliferyl-β-D-cellobioside (MU-CB). MUS-CB is not hydrolyzed by the catalytic domain of cellulase E1 from Acidothermus cellulolyticus under conditions where this enzyme rapidly degrades MU-CB. Thermodn. parameters describing the steady-state binding of MUS-CB to Thermobifida fusca cellulase Cel6A are similar to those for MU-CB, indicating that MUS-CB can be used in place of MU-CB to study binding events in the Cel6A active-site cleft. In the pre-steady-state, MUS-CB binds to Cel6A by a simple, one-step bimol. association reaction. It is anticipated that similar thio-containing 4-methylumbelliferyl compds. will have applications in studies of other enzyme systems.
IT 408540-58-9P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(4-Me-7-thioumbelliferyl-β-D-cellobioside can be used fluorescent nonhydrolyzable substrate analog for cellulases)
RN 408540-58-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(4-O-β-D-glucopyranosyl-β-D-

glucopyranosyl)thio]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:966982 HCAPLUS
DOCUMENT NUMBER: 124:176742
TITLE: Synthesis of fluorescent 4-methyl-7-thiocoumaryl S-glycosides of sialic acid
AUTHOR(S): Tanaka, Makoto; Kai, Toshitsugu; Sun, Xue-Long; Takayanagi, Hiroaki; Uda, Yutaka; Furuhata, Kimio
CORPORATE SOURCE: Sch. Pharmaceutical Sci., Kitasato Univ., Tokyo, 108, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1995), 43(11), 1844-8
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:176742
AB Condensation of 4-methyl-7-thiocoumarin sodium salt with Me 5-(acetylamino)-4,7,8,9-tetra-O-acetyl-2-chloro-2,3,5-trideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate, Me 5-(O-acetylglycolylamino)-4,7,8,9-tetra-O-acetyl-2-chloro-2,3,6-trideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate, and Me 4,5,7,8,9-penta-O-acetyl-2-chloro-2,3-dideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate under Williamson reaction conditions gave the corresponding α-glycosides in good yields. Deprotection of these α-glycosides gave three new fluorogenic substrates, the 4-methylcoumarin-7-yl S-glycosides of N-acetylneuraminic acid, N-glycolylneuraminic acid, and 3-deoxy-D-glycero-D-galacto-2-nonulopyranosonic acid (KDN). Also prepared was benzyl 5-amino-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosidonic acid, a key intermediate for the synthesis of N-glycolylneuraminic acid.
IT 173599-83-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sialic acid methylcoumaryl thioglycosides as fluorogenic substrates)
RN 173599-83-2 HCAPLUS
CN α-Neuraminic acid, N-acetyl-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 173599-86-5P 173599-88-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sialic acid methylcoumaryl thioglycosides as fluorogenic substrates)

RN 173599-86-5 HCAPLUS

CN α-Neuraminic acid, N-[(acetyloxy)acetyl]-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 173599-88-7 HCAPLUS

CN D-glycero-α-D-galacto-2-Nonulopyranosidonic acid, 4-methyl-2-oxo-2H-1-benzopyran-7-yl 3-deoxy-2-thio-, methyl ester, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 173599-84-3P 173599-87-6P 173599-89-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of sialic acid methylcoumaryl thioglycosides as fluorogenic substrates)
RN 173599-84-3 HCAPLUS
CN α-Neuraminic acid, N-acetyl-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 173599-87-6 HCAPLUS
CN α-Neuraminic acid, N-(hydroxyacetyl)-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 173599-89-8 HCAPLUS
CN D-glycero-α-D-galacto-2-Nonulopyranosidonic acid, 4-methyl-2-oxo-2H-1-benzopyran-7-yl 3-deoxy-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:656557 HCAPLUS
DOCUMENT NUMBER: 115:256557
TITLE: Preparation of benzopyranyl β-D-thioxyloside analogs as antithrombotics
INVENTOR(S): Samreth, Soth; Barberousse, Veronique; Renaut, Patrice; Bellamy, Francois; Millet, Jean
PATENT ASSIGNEE(S): Fournier Innovation et Synergie, Fr.
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 421829	A1	19910410	EP 1990-402403	19900831	<--
EP 421829	B1	19941109			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
FR 2652353	A1	19910329	FR 1989-12452	19890922	<--
FR 2652353	B1	19940211			
FR 2659659	A1	19910920	FR 1990-3401	19900316	<--
FR 2659659	B1	19950310			
CA 2024476	A1	19910323	CA 1990-2024476	19900831	<--
CA 2024476	C	19991012			
ES 2066165	T3	19950301	ES 1990-402403	19900831	<--
IL 95582	A	20010614	IL 1990-95582	19900904	<--
US 5169838	A	19921208	US 1990-579702	19900910	<--
AU 9062531	A	19910328	AU 1990-62531	19900917	<--
AU 631456	B2	19921126			
NO 9004088	A	19910325	NO 1990-4088	19900919	<--
NO 172987	B	19930628			
NO 172987	C	19931006			
FI 100183	B	19971015	FI 1990-4614	19900919	<--
FI 100183	B1	19971015			
CN 1050544	A	19910410	CN 1990-107856	19900921	<--
CN 1027268	B	19950104			
JP 03120292	A	19910522	JP 1990-253983	19900921	<--
JP 07103147	B	19951108			
HU 55794	A2	19910628	HU 1990-6005	19900921	<--
HU 207867	B	19930628			
ZA 9007567	A	19910828	ZA 1990-7567	19900921	<--
DD 297649	A5	19920116	DD 1990-344131	19900921	<--
SU 1838323	A3	19930830	SU 1990-4831306	19900921	<--
CZ 286343	B6	20000315	CZ 1990-4638	19900924	<--
SK 280827	B6	20000814	SK 1990-4638	19900924	<--
AU 9225397	A	19921126	AU 1992-25397	19920928	<--
AU 642829	B2	19931028			

PRIORITY APPLN. INFO.: FR 1989-12452 A 19890922
FR 1990-3401 A 19900316
CS 1990-4638 A 19900924

OTHER SOURCE(S): CASREACT 115:256557; MARPAT 115:256557
GI



I

II



III

AB The title compds. [I; II; R, R1 = H, (substituted) alkyl, etc.; X = S, O; Y = H, acyl] were prepared 4-Ethyl-7-hydroxy-2H-1-benzopyran-2-one in toluene-MeCN containing ZnCl2 and Ag imidazolate was treated with 2,3,4-tri-O-acetyl-5-thio-D-xylopyranosyl bromide at 55° for 24 h to give 17% title compound III, which at 3 mg/kg p.o. showed 65% inhibition of activated factor X-induced hypercoagulation in rats.

IT 137214-70-1P 137214-71-2P 137214-95-0P
137214-96-1P 137214-97-2P 137214-98-3P
137214-99-4P 137215-08-8P 137215-09-9P
137215-10-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antithrombotic)

RN 137214-70-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-71-2 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-chloro-4-methyl-7-[(5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-95-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-96-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-97-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-chloro-4-methyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-98-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-ethyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-99-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-propyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137215-08-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(5-thio-β-D-xylopyranosyl)thio]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 137215-09-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-ethyl-7-[(5-thio-β-D-xylopyranosyl)thio]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 137215-10-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-propyl-7-[(5-thio-β-D-xylopyranosyl)thio]-
(CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:91839 HCAPLUS
DOCUMENT NUMBER: 114:91839
TITLE: Silver halide color photographic photosensitive material
INVENTOR(S): Ichijima, Yasushi; Takamoto, Kunio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02157752	A	19900618	JP 1988-311521	19881209 <--

PRIORITY APPLN. INFO.: JP 1988-311521 19881209
GI



A

AB In the title material having on a support at least 1 Ag halide emulsion layer, the material contains at least 1 kind of compds. A (Cp = a group capable of releasing a DYE-Ballast group upon coupling with an oxidized developing agent; DYE-Ballast group is capable of becoming a fluorescent compound by separating from the Cp group; Sol is an alkali-soluble group; n = 0, 1; Ballast is a diffusion-resistive group).

IT 132226-72-3
RL: USES (Uses)
(silver halide color photog. photosensitive materials containing)
RN 132226-72-3 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[4-[[6-chloro-3-[2-(hexadecyloxy)-2-oxoethyl]-2-oxo-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]thio]-1-(2-chlorophenyl)-4,5-dihydro-5-oxo-1H-pyrazol-3-yl]amino]- (CA INDEX NAME)



=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1332992 HCAPLUS

DOCUMENT NUMBER: 148:11252
TITLE: Preparation of substituted purinamines as antitumor agents
INVENTOR(S): Bajji, Ashok C.; Kim, Se-Ho; Markovitz, Benjamin; Trovato, Richard; Tangallapally, Rajendra; Anderson, Mark B.; Wettstein, Daniel; Shenderovich, Mark; Vanecko, John A.
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 477pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2007134298	A2	20071122	WO 2007-US68899		20070514
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
US 2007299258	A1	20071227	US 2007-748362		20070514
PRIORITY APPLN. INFO.:			US 2006-799874P	P	20060512
			US 2006-822159P	P	20060811
			US 2006-865140P	P	20061109
			US 2007-883707P	P	20070105

OTHER SOURCE(S): MARPAT 148:11252
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I-III [A, B = (un)substituted aryl, heteroaryl, heterocyclyl, cycloalkyl; R1 = H, alkyl, aryl, heteroaryl, etc.; L1, L2 = (CH2)n(CH2)n, (CH2)nC(O)(CH2)n, (CH2)nC(O)N(CH2)n, etc.; n = 0-8], useful for treating Hsp90 dependent disorders such as cancer, were prepared and claimed. Thus, reacting 8-(2,5-dimethoxyphenylsulfanyl)-9H-purin-6-ylamine with (2-bromoethyl)benzene in the presence of Barton's base in DMF afforded 9% IV and 8% V. Compds. I were evaluated for binding to purified Hsp90 (data given).

IT 958021-33-5P 958021-35-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted purinamines as antitumor agents)

RN 958021-33-5 HCAPLUS

CN 1-Piperidinecarboxaldehyde, 4-[2-[6-amino-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-9H-purin-9-yl]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 958021-32-4
CMF C23 H24 N6 O3 S





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 958021-35-7 HCAPLUS
CN 1-Piperidinecarboxaldehyde, 4-[2-[6-amino-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-3H-purin-3-yl]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 958021-34-6
CMF C23 H24 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 958026-29-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted purinamines as antitumor agents)
RN 958026-29-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(6-amino-9H-purin-8-yl)thio]-4-methyl- (CA INDEX NAME)



L7 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:906571 HCAPLUS
DOCUMENT NUMBER: 147:277446
TITLE: Preparation of coumarin derivatives as antitumor agents

INVENTOR(S): Iikura, Hitoshi; Hyoudoh, Ikumi; Aoki, Toshihiro; Furuichi, Noriyuki; Matsushita, Masayuki; Watanabe, Fumio; Ozawa, Sawako; Sakaitani, Masahiro; Ho, Pil-Su; Tomii, Yasushi; Takanashi, Kenji; Harada, Naoki
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 439pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007091736	A1	20070816	WO 2007-JP52800	20070209

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2006-32903 A 20060209
OTHER SOURCE(S): MARPAT 147:277446
GI



I

AB The title compds. I [G1, G2, G3, G8 = N, CR1, C(G9X); one of G1, G2, G3, G8 is C(G9X); X = (un)substituted alkyl, aryl, heteroaryl, etc.; G9 = single bond, O, S, etc.; R1 = H, halo, cyano, etc.; ring G6 = divalent aryl, divalent heterocyclyl; A = R5NSO2NR6R7, R8NSO2CH2CONR9R10; G4 = O, S, etc.; G5 = O, CH2, S, etc. ; G7 = O, CONR44, NR44CO, etc.; further details related to G1, G2, G3, G8, X are given; R2 = OH, alkoxy, (un)substituted alkyl, etc.; R6, R7, R9, R10 = H, alkoxy, cycloalkyl, etc.; R5, R8, R44 = H, alkyl] are prepared Thus, dimethylcarbamic acid 3-(2-fluoro-3-(aminosulfonyl)aminobenzyl)-6-fluoro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester was prepared in a multistep process starting from Et acetoacetate and 1-bromomethyl-2-fluoro-3-nitrobenzene. In an assay using human colon cancer cells HCT116, compds. of this invention showed IC50

values of 0.0015 μM to 0.036 μM.

IT 946128-79-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of coumarin derivs. as antitumor agents)

RN 946128-79-6 HCAPLUS

CN Sulfamide, N-[2-fluoro-3-[[4-methyl-2-oxo-7-(2-pyrimidinylthio)-2H-1-benzopyran-3-yl]methyl]phenyl]-N'-methyl- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:61695 HCAPLUS
DOCUMENT NUMBER: 146:156228
TITLE: Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
INVENTOR(S): Kooijman, Ron; Gerlo, Sarah; Verdood, Peggy
PATENT ASSIGNEE(S): Vrije Universiteit Brussel, Belg.
SOURCE: PCT Int. Appl., 64pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007006544	A2	20070118	WO 2006-EP6761	20060711
WO 2007006544	A3	20070518		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: WO 2005-EP7550 A 20050712
OTHER SOURCE(S): MARPAT 146:156228

AB The invention is related to the finding that certain analogs of cAMP, e.g.

8-(4-chlorophenylthio)-2'- O- methyladenosine- 3', 5'- cyclic monophosphate (8-pCPT-2'-O-Me-cAMP) specifically blocks the production of interleukin 10 (IL-10) in human T cells. It is also related to the finding that the production of other cytokines (e.g. IL-2, IL-4, IL-5, IL-6, IL-12 and interferon γ) is not affected by these analogs. The finding may be used as a treatment of conditions which respond to a reduced level of IL-10 and/or by a change in the balance of the Th1 and Th2 responses. It may be used in research and in testing for dysfunctional EPAC protein and IL-10 producing pathways.

IT 634208-08-5 634208-08-5D, derivs., metabolites, and stereoisomers
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cAMP derivs. for treatment of immune-related disorders)

RN 634208-08-5 HCAPLUS
CN Adenosine, 2'-O-methyl-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-, cyclic 3',5'-(hydrogen phosphate) (CA INDEX NAME)

Absolute stereochemistry.



RN 634208-08-5 HCAPLUS
CN Adenosine, 2'-O-methyl-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-, cyclic 3',5'-(hydrogen phosphate) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:548997 HCAPLUS
DOCUMENT NUMBER: 145:189099
TITLE: A highly concise preparation of O-deacetylated arylthioglycosides of N-acetyl-D-glucosamine from 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride and aryl thiols or disulfides
AUTHOR(S): Stubbs, Keith A.; Macauley, Matthew S.; Vocadlo, David J.
CORPORATE SOURCE: Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Can.
SOURCE: Carbohydrate Research (2006), 341(10), 1764-1769
CODEN: CRBRAT; ISSN: 0008-6215
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:189099
AB An expedient and mild route to a range of aryl 2-acetamido-2-deoxy-1-thio-β-D-glucopyranosides has been devised from 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride and arylthiols or aryl disulfides using phase transfer catalysis conditions. This simple procedure compresses up to three synthetic steps into a one-pot reaction, obviating the need for tedious workups and chromatog. and directly furnishes crystalline materials in good yields. The procedure is compatible with a range of thiols and disulfides and may be amenable for preparing a wide range of thioglycosides with various glycons and aglycons.
IT 903569-39-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(phase transfer catalysis preparation of N-acetyl-D-glucosamine O-deacetylated arylthioglycosides from 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride and aryl thiols or disulfides)
RN 903569-39-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]thio]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1211751 HCAPLUS
DOCUMENT NUMBER: 144:102799

TITLE: O-GlcNAcase Catalyzes Cleavage of Thioglycosides without General Acid Catalysis
AUTHOR(S): Macauley, Matthew S.; Stubbs, Keith A.; Vocadlo, David J.
CORPORATE SOURCE: Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Can.
SOURCE: Journal of the American Chemical Society (2005), 127(49), 17202-17203
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:102799
AB O-GlcNAcase catalyzes the removal of N-acetylglucosamine residues from serine and threonine residues of post-translationally modified proteins using a catalytic mechanism involving substrate-assisted catalysis and general acid/base catalysis. Since thioglycosides are widely perceived as resistant to hydrolysis by glycosidases, it was surprising to find that O-GlcNAcase also catalyzes the efficient hydrolysis of S-glycosides. Bronsted analyses and pH-activity studies of the O-GlcNAcase-catalyzed hydrolysis of a series of aryl S- and O-glycosides reveal that O-GlcNAcase effects hydrolysis of thioglycosides without the assistance of general acid catalysis. α-Deuterium kinetic isotope effects for O- and S-glycosides, as well as Taft-like analyses using N-fluoroacetyl-β-glycosides, suggest that O-GlcNAcase accomplishes hydrolysis of thioglycosides by stabilizing late transition states. For S-glycosides this transition state shows greater nucleophilic participation from the 2-acetamido group than for O-glycosides. The rate consts. governing the O-GlcNAcase-catalyzed hydrolysis of O- and S-glycosides as compared to those previously determined for the spontaneous hydrolysis of structurally similar O,O- and O,S-acetals show a similar ratio. O-GlcNAcase therefore demonstrates similar catalytic proficiency toward both O- and S-glycosides. We conclude that O-GlcNAcase is a bifunctional catalyst capable of efficiently cleaving thioglycosides without general acid catalysis, an observation that may have biol. implications.
IT 872618-20-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(O-GlcNAcase catalyzes cleavage of thioglycosides through stabilization of transition state)
RN 872618-20-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-methyl-7-[[3,4,6-tri-O-acetyl-2-deoxy-2-[(fluoroacetyl)amino]-β-D-glucopyranosyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 872618-22-9P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(O-GlcNAcase catalyzes cleavage of thioglycosides through stabilization of transition state)
RN 872618-22-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[2-deoxy-2-[(fluoroacetyl)amino]-β-D-glucopyranosyl]thio]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:991527 HCAPLUS
DOCUMENT NUMBER: 140:28025
TITLE: Preparation of cyclic nucleotides for modulating the activity of exchange proteins directly activated by cAMP (Epacs)
INVENTOR(S): De Koning, John; Christensen, Anne; Schwede, Frank; Genieser, Hans Gottfried; Doskeland, Stein; Bos, Johannes
PATENT ASSIGNEE(S): Kylix, B. V., Neth.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104250	A1	20031218	WO 2003-EP6120	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488611	A1	20031218	CA 2003-2488611	20030610
AU 2003242672	A1	20031222	AU 2003-242672	20030610
EP 1511757	A1	20050309	EP 2003-757062	20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005532360	T	20051027	JP 2004-511318	20030610
US 2006100166	A1	20060511	US 2005-517564	20051215

PRIORITY APPLN. INFO.: EP 2002-77219 A 20020607
WO 2003-EP6120 W 20030610

OTHER SOURCE(S): MARPAT 140:28025
GI



I

AB The present invention relates to novel cyclic nucleotides I and deaza analogs, wherein R1 can be independently H, halogen, azido, alkyl, aryl, amido-alkyl, amido-aryl, OH, O-alkyl, O-aryl, SH, S-alkyl, Saryl, SeH, Se-alkyl, Se-aryl, amino, NH-alkyl, NH-aryl, Nbisalkyl, N-bisaryl, cycloalkylamino; R2 can be independently H, halogen, azido, O-alkyl, Salkyl, Se-alkyl, NH-alkyl, N-bisalkyl, alkyl-carbamoyl, cycloalkylamino, silyl; R3 can be independently H, halogen, OH, azido, amidoalkyl, amido-aryl, O-alkyl, O-aryl, SH, S-alkyl, S-aryl, amino, NH-alkyl,

NH-aryl, N-bisalkyl, N-bisaryl, NH-alkylcarbamoyl, cycloalkylamino; and wherein R4 is O(H) or S(H); and R5 is O(H), S(H), amino, H, alkyl, O-alkyl, O-aryl, S-alkyl, S-aryl, NH-alkyl, NH-aryl, N-bisalkyl, N-bisaryl; or R4is O(H), S(H), amino, H, alkyl, O-alkyl, O-aryl, Salkyl, S-aryl, NH-alkyl, NH-aryl, N-bisalkyl, N-bisaryl; and R5 is O(H) or S(H); for modulating the activity of exchange proteins directly activated by cAMP (Epacs). In particular, the present invention relates to cAMP analogs that specifically modulate the activity of Epacs. The invention further relates to pharmaceutical compns. comprising the novel compds., and the use of the compds. in the treatment of humans and/or animals. Cyclic nucleotides were prepared as antitumor, antithrombotic, and antiinflammatory agents, for discriminating between Epac- and PKA-mediated signal transduction pathways, and for R10 the treatment of type-2 diabetes mellitus. Thus, 8-bromo-2'-deoxyadenosine-3',5'-cyclic monophosphate was prepared and tested for modulating the activity of exchange proteins directly activated by cAMP.for modulating the activity of exchange proteins directly activated by cAMP. In summary, these findings suggest multiple therapeutic applications for cAMP analogs that specifically modulate the activity of Epacs, like 2'-O-Me-cAMP, including treatment of cancer, chronic inflammation, thrombosis, and type-2 diabetes mellitus. In addition, a large number of other new compds. were tested for their effect on Epac and PKA. Since phosphorothioate-modified cyclic nucleotides are known to be considerably protected from hydrolysis by cyclic nucleotide responsive phosphodiesterases (PDE), corresponding analogs were prepared as well, in order to obtain PDE-resistant tools, where necessary, e.g. for long term incubation expts.

IT 634207-77-5P 634208-08-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic nucleotides for modulating activity of exchange proteins directly activated by camp epacs)

RN 634207-77-5 HCAPLUS
CN Adenosine, 2'-O-methyl-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-, cyclic 3',5'-(hydrogen phosphate), monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 634208-08-5 HCAPLUS
CN Adenosine, 2'-O-methyl-8-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)thio]-, cyclic 3',5'-(hydrogen phosphate) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:144986 HCAPLUS
DOCUMENT NUMBER: 136:290922
TITLE: 4-Methyl-7-thioumbelliferyl-β-D-cellobioside: A Fluorescent, Nonhydrolyzable Substrate Analogue for Cellulases
AUTHOR(S): Barr, Brian K.; Holewinski, Ronald J.
CORPORATE SOURCE: Department of Chemistry, Loyola College in Maryland, Baltimore, MD, 21210-2699, USA
SOURCE: Biochemistry (2002), 41(13), 4447-4452
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:290922

AB The kinetics of cellulose binding and hydrolysis by cellulases is not well understood except at steady-state conditions. For use in studies of cellulase pre-steady-state and steady-state kinetics, we have prepared 4-methyl-7-thioumbelliferyl-β-D-cellobioside (MUS-CB), a ground-state nonhydrolyzable analog of the fluorescent cellulase substrate 4-methylumbelliferyl-β-D-cellobioside (MU-CB). MUS-CB is not hydrolyzed by the catalytic domain of cellulase E1 from Acidothermus cellulolyticus under conditions where this enzyme rapidly degrades MU-CB. Thermodn. parameters describing the steady-state binding of MUS-CB to Thermobifida fusca cellulase Cel6A are similar to those for MU-CB, indicating that MUS-CB can be used in place of MU-CB to study binding events in the Cel6A active-site cleft. In the pre-steady-state, MUS-CB binds to Cel6A by a simple, one-step bimol. association reaction. It is anticipated that similar thio-containing 4-methylumbelliferyl compds. will have applications in studies of other enzyme systems.

IT 408540-58-9P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(4-Me-7-thioumbelliferyl-β-D-cellobioside can be used fluorescent nonhydrolyzable substrate analog for cellulases)

RN 408540-58-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(4-O-β-D-glucopyranosyl-β-D-glucopyranosyl)thio]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:966982 HCAPLUS
DOCUMENT NUMBER: 124:176742
TITLE: Synthesis of fluorescent 4-methyl-7-thiocoumaryl S-glycosides of sialic acid
AUTHOR(S): Tanaka, Makoto; Kai, Toshitsugu; Sun, Xue-Long; Takayanagi, Hiroaki; Uda, Yutaka; Furuhata, Kimio
CORPORATE SOURCE: Sch. Pharmaceutical Sci., Kitasato Univ., Tokyo, 108, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1995), 43(11), 1844-8

CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:176742

AB Condensation of 4-methyl-7-thiocoumarin sodium salt with Me 5-(acetylamino)-4,7,8,9-tetra-O-acetyl-2-chloro-2,3,5-trideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate, Me 5-(O-acetylglycolylamino)-4,7,8,9-tetra-O-acetyl-2-chloro-2,3,6-trideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate, and Me 4,5,7,8,9-penta-O-acetyl-2-chloro-2,3-dideoxy-D-glycero-β-D-galacto-2-nonulopyranosonate under Williamson reaction conditions gave the corresponding α-glycosides in good yields. Deprotection of these α-glycosides gave three new fluorogenic substrates, the 4-methylcoumarin-7-yl S-glycosides of N-acetylneuraminic acid, N-glycolylneuraminic acid, and 3-deoxy-D-glycero-D-galacto-2-nonulopyranosonic acid (KDN). Also prepared was benzyl 5-amino-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosidonic acid, a key intermediate for the synthesis of N-glycolylneuraminic acid.

IT 173599-83-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sialic acid methylcoumaryl thioglycosides as fluorogenic substrates)

RN 173599-83-2 HCAPLUS

CN α-Neuraminic acid, N-acetyl-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 173599-86-5P 173599-88-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sialic acid methylcoumaryl thioglycosides as fluorogenic substrates)

RN 173599-86-5 HCAPLUS

CN α-Neuraminic acid, N-[(acetyloxy)acetyl]-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 173599-88-7 HCAPLUS
CN D-glycero-α-D-galacto-2-Nonulopyranosidonic acid, 4-methyl-2-oxo-2H-1-benzopyran-7-yl 3-deoxy-2-thio-, methyl ester, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 173599-84-3P 173599-87-6P 173599-89-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of sialic acid methylcoumaryl thioglycosides as fluorogenic substrates)
RN 173599-84-3 HCAPLUS
CN α-Neuraminic acid, N-acetyl-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 173599-87-6 HCAPLUS
CN α-Neuraminic acid, N-(hydroxyacetyl)-2-S-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 173599-89-8 HCAPLUS
CN D-glycero-α-D-galacto-2-Nonulopyranosidonic acid, 4-methyl-2-oxo-2H-1-benzopyran-7-yl 3-deoxy-2-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:656557 HCAPLUS
DOCUMENT NUMBER: 115:256557
TITLE: Preparation of benzopyranyl β-D-thioxyloside analogs as antithrombotics
INVENTOR(S): Samreth, Soth; Barberousse, Veronique; Renaut, Patrice; Bellamy, Francois; Millet, Jean
PATENT ASSIGNEE(S): Fournier Innovation et Synergie, Fr.
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 421829	A1	19910410	EP 1990-402403	19900831
EP 421829	B1	19941109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2652353	A1	19910329	FR 1989-12452	19890922
FR 2652353	B1	19940211		
FR 2659659	A1	19910920	FR 1990-3401	19900316
FR 2659659	B1	19950310		
CA 2024476	A1	19910323	CA 1990-2024476	19900831
CA 2024476	C	19991012		
ES 2066165	T3	19950301	ES 1990-402403	19900831
IL 95582	A	20010614	IL 1990-95582	19900904
US 5169838	A	19921208	US 1990-579702	19900910
AU 9062531	A	19910328	AU 1990-62531	19900917
AU 631456	B2	19921126		
NO 9004088	A	19910325	NO 1990-4088	19900919
NO 172987	B	19930628		
NO 172987	C	19931006		
FI 100183	B	19971015	FI 1990-4614	19900919
FI 100183	B1	19971015		
CN 1050544	A	19910410	CN 1990-107856	19900921
CN 1027268	B	19950104		

JP 03120292	A	19910522	JP 1990-253983		19900921
JP 07103147	B	19951108			
HU 55794	A2	19910628	HU 1990-6005		19900921
HU 207867	B	19930628			
ZA 9007567	A	19910828	ZA 1990-7567		19900921
DD 297649	A5	19920116	DD 1990-344131		19900921
SU 1838323	A3	19930830	SU 1990-4831306		19900921
CZ 286343	B6	20000315	CZ 1990-4638		19900924
SK 280827	B6	20000814	SK 1990-4638		19900924
AU 9225397	A	19921126	AU 1992-25397		19920928
AU 642829	B2	19931028			
PRIORITY APPLN. INFO.:			FR 1989-12452	A	19890922
			FR 1990-3401	A	19900316
			CS 1990-4638	A	19900924

OTHER SOURCE(S): CASREACT 115:256557; MARPAT 115:256557

GI



I



II



III

AB The title compds. [I; II; R, R1 = H, (substituted) alkyl, etc.; X = S, O; Y = H, acyl] were prepared 4-Ethyl-7-hydroxy-2H-1-benzopyran-2-one in toluene-MeCN containing ZnCl2 and Ag imidazolate was treated with 2,3,4-tri-O-acetyl-5-thio-D-xylopyranosyl bromide at 55° for 24 h to give 17% title compound III, which at 3 mg/kg p.o. showed 65% inhibition of activated factor X-induced hypercoagulation in rats.

IT 137214-70-1P 137214-71-2P 137214-95-0P
137214-96-1P 137214-97-2P 137214-98-3P
137214-99-4P 137215-08-8P 137215-09-9P
137215-10-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antithrombotic)

RN 137214-70-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-71-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-chloro-4-methyl-7-[(5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-95-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-96-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-97-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 3-chloro-4-methyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-98-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-ethyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137214-99-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-propyl-7-[(2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137215-08-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(5-thio-β-D-xylopyranosyl)thio]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 137215-09-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-ethyl-7-[(5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 137215-10-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-propyl-7-[(5-thio-β-D-xylopyranosyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:91839 HCAPLUS
DOCUMENT NUMBER: 114:91839
TITLE: Silver halide color photographic photosensitive material
INVENTOR(S): Ichijima, Yasushi; Takamoto, Kunio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02157752	A	19900618	JP 1988-311521	19881209

PRIORITY APPLN. INFO.: JP 1988-311521 19881209
GI



AB In the title material having on a support at least 1 Ag halide emulsion layer, the material contains at least 1 kind of compds. A (Cp = a group capable of releasing a DYE-Ballast group upon coupling with an oxidized developing agent; DYE-Ballast group is capable of becoming a fluorescent compound by separating from the Cp group; Sol is an alkali-soluble group; n = 0, 1; Ballast is a diffusion-resistive group).
IT 132226-72-3
RL: USES (Uses)
(silver halide color photog. photosensitive materials containing)
RN 132226-72-3 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[4-[[6-chloro-3-[2-(hexadecyloxy)-2-oxoethyl]-2-oxo-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]thio]-1-(2-chlorophenyl)-4,5-dihydro-5-oxo-1H-pyrazol-3-yl]amino]- (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	111.34	469.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.00	-12.00

FILE 'REGISTRY' ENTERED AT 12:53:46 ON 22 FEB 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2008 HIGHEST RN 1005032-28-9
DICTIONARY FILE UPDATES: 21 FEB 2008 HIGHEST RN 1005032-28-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10559885b.str





chain nodes :
16 17 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
3-16 5-20 9-17 11-16
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-15 12-13 13-14
14-15
exact/norm bonds :
3-16 5-20 9-17 11-15 11-16 14-15
exact bonds :
5-6 5-10 7-8 8-9 9-10 11-12 12-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 : 11 :

G1:SO2,S,SO3H

G2:Cy,Hy,Ak,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 20:CLASS

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



G1 SO2,S,SO3H

G2 Cy,Hy,Ak,Ph

Structure attributes must be viewed using STN Express query preparation.

```
=> s l10
SAMPLE SEARCH INITIATED 12:54:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        3 TO ITERATE

100.0% PROCESSED        3 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            3 TO      163
PROJECTED ANSWERS:               3 TO      163

L11           3 SEA SSS SAM L10

=> s l10 sss full
FULL SEARCH INITIATED 12:54:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       53 TO ITERATE

100.0% PROCESSED       53 ITERATIONS                               49 ANSWERS
SEARCH TIME: 00.00.01

L12          49 SEA SSS FUL L10

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     647.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

FILE 'HCAPLUS' ENTERED AT 12:54:19 ON 22 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 22 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 21 Feb 2008 (20080221/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l12
L13 1 L12

=> d l13 ibib abs hitstr tot

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1080900 HCAPLUS
DOCUMENT NUMBER: 142:56291
TITLE: Preparation of (thiazolylthio)coumarin derivatives as leukotriene biosynthesis inhibitors
INVENTOR(S): Gareau, Yves; Juteau, Helene; Mackay, Bruce D.; Friesen, Richard; Grimm, Erich L.; Blouin, Marc; Laliberte, Sebastien
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108720	A1	20041216	WO 2004-CA861	20040608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004245146	A1	20041216	AU 2004-245146	20040608
CA 2527769	A1	20041216	CA 2004-2527769	20040608

EP 1636222		A1	20060322	EP 2004-737802		20040608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK						
CN 1802372		A	20060712	CN 2004-80016015		20040608
JP 2006527207		T	20061130	JP 2006-515589		20040608
US 2006116406		A1	20060601	US 2005-559885		20051207
IN 2005DN05947		A	20080104	IN 2005-DN5947		20051220
PRIORITY APPLN. INFO.:				US 2003-477854P	P	20030611
				US 2003-511038P	P	20031014
				WO 2004-CA861	W	20040608

OTHER SOURCE(S): MARPAT 142:56291

GI



I



II

AB Title compds. represented by the formula I [wherein R1 = H or (cyclo)alkyl; R2 = H, OH, oxyalkyl, etc.; R3, R4 = independently H, CF3, (un)substituted alkyl, etc.; R3R4 = cycloalkyl or cycloalkenyl ring; R5, R6 = independently H, (cyclo)alkyl, halo; A = aryl, Ph, (cyclo)alkyl, etc.; and pharmaceutically acceptable salts or esters thereof] were prepared as leukotriene biosynthesis inhibitors (no data). For example, II was given in a multi-step synthesis starting from the reaction of 7-bromo-4-(trifluoromethanesulfonyloxy)coumarin with 4-fluorophenylboronic acid. Processes for preparation and methods of using the compds. I in human polymorphonuclear leukocyte LTB4, human 5-lipoxygenase enzyme and 5-lipoxygenase human whole blood assay are provided. I and their pharmaceutical compns. are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-atherosclerotic agents.

IT 808140-37-6P 808140-43-4P, (+)-(3R)-4,4,4-Trifluoro-3-[2-[[4-(4-fluorophenyl)-2-oxo-2H-chromen-7-yl]thio]-1,3-thiazol-5-yl]-3-hydroxybutanoic acid 808140-52-5P, 7-[[5-[(1S)-1-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-phenyl-2H-chromen-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 7-[(1,3-thiazol-2-yl)thio]coumarin derivs. as leukotriene

biosynthesis inhibitors)
RN 808140-37-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 808140-43-4 HCAPLUS
CN 5-Thiazolepropanoic acid, 2-[[4-(4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]thio]-β-hydroxy-β-(trifluoromethyl)-, (βR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 808140-52-5 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 808140-31-0P, 4-(4-Fluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-32-1P, 4-(4-Fluorophenyl)-7-[[5-(1-hydroxycyclopentyl)-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-33-2P, 4-(4-Fluorophenyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-34-3P, 7-[[5-(1-Ethylpropyl)-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-35-4P, 4-(4-Fluorophenyl)-3-methyl-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-36-5P, (+)-(S)-4-(4-Fluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-39-8P, 7-[[5-[Dicyclopropyl(hydroxy)methyl]-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-40-1P, 7-[[5-[Dicyclopropyl(hydroxy)methyl]-1,3-thiazol-2-yl]thio]-4-(pyridin-3-yl)-2H-chromen-2-one 808140-41-2P, 7-[[5-[1,3-Dihydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-42-3P, 7-[[5-[(1R)-1,3-Dihydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-44-5P, (-)-(3S)-4,4,4-Trifluoro-3-[2-[[4-(4-fluorophenyl)-2-oxo-2H-chromen-7-yl]thio]-1,3-thiazol-5-yl]-3-hydroxybutanoic acid 808140-45-6P 808140-46-7P 808140-47-8P, 7-[[4-(1-Ethyl-1-hydroxypropyl)-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-48-9P 808140-49-0P 808140-50-3P 808140-51-4P 808140-53-6P, 7-[[5-[(1R)-1-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-phenyl-2H-chromen-2-one 808140-54-7P, 4-(4-Fluorophenyl)-8-methyl-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-55-8P, 4-(3,5-Difluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-56-9P, 4-[3-(Cyclopropyloxy)phenyl]-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-57-0P, 4-(3-Methoxyphenyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-58-1P, 7-[[5-[(1R)-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(3-methoxyphenyl)-2H-chromen-2-one 808140-59-2P, 7-[[5-[(1R)-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(pyridin-3-yl)-2H-chromen-2-one 808140-60-5P , 7-[[5-[(1S)-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(pyridin-3-yl)-2H-chromen-2-one 808140-61-6P, 4-(4-Fluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)prop-2-en-1-yl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-62-7P, 7-[[5-[1-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(2-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one 808140-63-8P 808140-64-9P, 4-(4-Fluorophenyl)-7-[[5-[(R)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]sulfonyl]-2H-chromen-2-one

808140-65-0P, 4-Phenyl-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-66-1P, 4-(Pyridin-3-yl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-67-2P, 4-(2-Methyl-1,3-thiazol-4-yl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-68-3P, 4-(2-Methyl-1,3-oxazol-4-yl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-69-4P, 4-(1,3-Thiazol-4-yl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1,3-thiazol-2-yl]thio]-2H-chromen-2-one 808140-70-7P, 7-[[5-[Dicyclopropyl(hydroxy)methyl]-1,3-thiazol-2-yl]thio]-4-phenyl-2H-chromen-2-one 808140-71-8P 808140-72-9P, 7-[[5-(Dicyclopropylmethyl)-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-73-0P, 7-[[5-(Dicyclopropylmethyl)-1,3-thiazol-2-yl]thio]-4-(pyridin-3-yl)-2H-chromen-2-one 808140-74-1P, 7-[[5-(1-Cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-1,3-thiazol-2-yl]thio]-4-(3-methylphenyl)-2H-chromen-2-one 808140-75-2P, 7-[[5-[Dicyclopropyl(hydroxy)methyl]-1,3-thiazol-2-yl]thio]-4-(2-methyl-1,3-thiazol-4-yl)-2H-chromen-2-one 808140-76-3P, 7-[[5-[Dicyclopropyl(hydroxy)methyl]-1,3-thiazol-2-yl]thio]-4-(pyrimidin-5-yl)-2H-chromen-2-one 808140-77-4P, 7-[[5-[(1R)-1-Hydroxy-1-(trifluoromethyl)propyl]-1,3-thiazol-2-yl]thio]-4-(3-methylphenyl)-2H-chromen-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-[(1,3-thiazol-2-yl)thio]coumarin derivs. as leukotriene biosynthesis inhibitors)

RN 808140-31-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-32-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-(1-hydroxycyclopentyl)-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-33-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-34-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-ethylpropyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-35-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-3-methyl-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-36-5 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 808140-39-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylhydroxymethyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-40-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylhydroxymethyl)-2-thiazolyl]thio]-4-(3-pyridinyl)- (CA INDEX NAME)



RN 808140-41-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[1,3-dihydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-42-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1R)-1,3-dihydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-44-5 HCAPLUS
CN 5-Thiazolepropanoic acid, 2-[[4-(4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]thio]-β-hydroxy-β-(trifluoromethyl)-, (βS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 808140-45-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-(1-hydroxy-1-methylpropyl)-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-46-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-(1-methylpropyl)-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-47-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[4-(1-ethyl-1-hydroxypropyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-48-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)-, (+)- (CA INDEX NAME)

Rotation (+).



RN 808140-49-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 808140-50-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-2-thiazolyl]thio]-4-(3-pyridinyl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 808140-51-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-2-thiazolyl]thio]-4-(3-pyridinyl)-, (+)- (CA INDEX NAME)

Rotation (+).



RN 808140-53-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-54-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-8-methyl-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-55-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(3,5-difluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-56-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-[3-(cyclopropyloxy)phenyl]-7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-57-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(3-methoxyphenyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-58-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(3-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-59-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-60-5 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(3-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-61-6 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[1-hydroxy-1-(trifluoromethyl)-2-propenyl]-2-thiazolyl]thio]- (9CI) (CA INDEX NAME)



RN 808140-62-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(2-methyl-4-thiazolyl)- (CA INDEX NAME)



RN 808140-63-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]sulfinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-64-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 808140-65-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-phenyl-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-66-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(3-pyridinyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-

(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-67-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(2-methyl-4-thiazolyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-68-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(2-methyl-4-oxazolyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-69-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 4-(4-thiazolyl)-7-[[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 808140-70-7 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylhydroxymethyl)-2-thiazolyl]thio]-4-phenyl- (CA INDEX NAME)



RN 808140-71-8 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylhydroxymethyl)-4-methyl-2-thiazolyl]thio]-4-phenyl- (CA INDEX NAME)



RN 808140-72-9 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylmethyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-73-0 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylmethyl)-2-thiazolyl]thio]-4-(3-pyridinyl)- (CA INDEX NAME)



RN 808140-74-1 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)-2-thiazolyl]thio]-4-(3-methylphenyl)- (CA INDEX NAME)



RN 808140-75-2 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylhydroxymethyl)-2-thiazolyl]thio]-4-(2-methyl-4-thiazolyl)- (CA INDEX NAME)



RN 808140-76-3 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(dicyclopropylhydroxymethyl)-2-thiazolyl]thio]-4-(5-pyrimidinyl)- (CA INDEX NAME)



RN 808140-77-4 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[(1R)-1-hydroxy-1-(trifluoromethyl)propyl]-2-thiazolyl]thio]-4-(3-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 808140-78-5P, 7-[[5-(1-Ethyl-1-hydroxypropyl)-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-86-5P, 7-[[5-[1-(1,3-Dioxolan-2-ylmethyl)-2,2,2-trifluoro-1-hydroxyethyl]-1,3-thiazol-2-yl]thio]-4-(4-fluorophenyl)-2H-chromen-2-one 808140-87-6P, Methyl (3R)-4,4,4-trifluoro-3-[2-[[4-(4-fluorophenyl)-2-oxo-2H-chromen-7-yl]thio]-1,3-thiazol-5-yl]-3-hydroxybutanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 7-[(1,3-thiazol-2-yl)thio]coumarin derivs. as leukotriene biosynthesis inhibitors)
RN 808140-78-5 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-(1-ethyl-1-hydroxypropyl)-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-86-5 HCAPLUS
CN 2H-1-Benzopyran-2-one, 7-[[5-[1-(1,3-dioxolan-2-ylmethyl)-2,2,2-trifluoro-1-hydroxyethyl]-2-thiazolyl]thio]-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 808140-87-6 HCAPLUS
CN 5-Thiazolepropanoic acid, 2-[[4-(4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]thio]-β-hydroxy-β-(trifluoromethyl)-, methyl ester, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.59	669.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.80	-12.80

STN INTERNATIONAL LOGOFF AT 12:57:50 ON 22 FEB 2008